Shares of LatentView Analytics Limited rose approximately 14% on April 2 after the company announced the completion of a $3 million strategic investment in Healtheon AI, a company focused on agentic artificial intelligence solutions for healthcare Revenue Cycle Management.
The stock opened at ₹259.90 against its previous close of ₹261.20, touching a session high of ₹302.70 and a low of ₹256.75. The 52-week range stands between ₹248.00 and ₹517.50.
According to the company’s press release, the investment was completed as a single tranche via a SAFE note. Under the partnership, LatentView will serve as a preferred deployment partner for Healtheon AI with its customers, combining LatentView’s data analytics capabilities with Healtheon AI’s healthcare-specific agentic AI platform.
Healtheon AI’s platform deploys specialised, role-based AI agents in a decentralised system designed to handle healthcare finance workflows including eligibility verification, prior authorisation, medical coding, claims processing, and denial remediation. The system is built for real-time processing at scale, with performance contracts linked to measurable reductions in Revenue Cycle Management labour costs and denial leakage.
Rajan Sethuraman, CEO of LatentView Analytics, stated that the investment aligns with the company’s AI-first strategy and positions it to deliver advanced technology solutions to clients in the healthcare sector. CFO Rajan Venkatesan described the transaction as consistent with the company’s build-invest-partner approach to becoming an AI-led organisation.
LatentView Analytics is a global data analytics company serving over 50 Fortune 500 companies across technology, consumer goods, industrials, financial services, and retail sectors.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Comments are closed.